Insulin Syringes Market Qualitative Insights on Application & Outlook by Share, Future Growth

Insulin syringes market was valued at $1,561.20 million in 2020, and is projected to reach $2,401.51 million by 2030, registering a CAGR of 4.4% from 2021 to 2030.

An insulin syringe aids in delivering insulin to diabetic patients in required doses. The insulin syringes consist of three parts-a needles, a barrel, and a plunger, and is available in various sizes. The needle is usually thin and short and covered with a special material such as silicone in order to allow it to slide through the skin causing minimal pain. Barrel is the chamber that holds the insulin. It is marked with calibrations designed to show the units of insulin being injected. The plunger is the narrow rod that slides up and down the length of the barrel. it serves to either draw the insulin into the barrel or release the insulin from the barrel through the needle. Further, the size of the insulin syringe is selected based on the desired dosage of insulin to be administered to diabetic patients.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :

Novo Nordisk A/S
Biocon Ltd
Abbott Laboratories
Terumo Corporation
Cardinal Health Inc
Beckton and Dickinson Company
Eli Lilly and Company
Nipro Medical Corporation
Medline Industries
Hindustan syringe and medical device Ltd.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3740

𝐆𝐞𝐭 𝐔𝐩 𝐓𝐨 𝟏𝟎% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭, 𝐓𝐢𝐥𝐥 𝐭𝐡𝐞 𝐃𝐚𝐭𝐞 𝟐𝟎𝐭𝐡 𝐨𝐟 𝐀𝐮𝐠𝐮𝐬𝐭 𝟐𝟎𝟐𝟐.

𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. Lockdown, government regulations, and continuous increase in infection rate across the country created a widespread financial impact on neurology hospitals and clinics. Large number of hospitals and clinics have witnessed a drop in number of patient visits amid COVID-19 ultimately reducing client contact.

The overall impact of COVID -19 remain positive for insulin syringe market. As patients with different health issues such as, diabetes, and high blood pressure are at higher risk of getting affected by this virus. It is found that the mortality rate is high in a patient with diabetes compared to the general population. The people living having diabetes require continuous access to insulin (administrated with syringes or pens) and care. Without or irregular supply of insulin devices due to pandemic can seriously affect the health of a person with diabetes especially who are diagnosed with type-1 diabetes as they are totally dependent on insulin. In addition, according to National Center of Biotechnology Information diabetes is treated with angiotensin converting enzymes inhibitors and this has been discovered that coronavirus binds to the target cells through this enzyme, an enzyme expressed in the blood vessels and lungs. As an increasing level of ACE2 enzyme founded in diabetic patients, the chances of COVID-19 also increase in such patients. Thus, the adoption of insulin syringes and continuous glucose monitoring devices has increased for close monitoring and optimal management of diabetes.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/3740

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

• On the basis of syringe size, the 3/10cc syringe segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period.
• On the basis of end user, the hospital & clinics industries segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period.
• Region wise, North America is held the largest market share in 2020, and is expected to remain dominant throughout the forecast period
• Asia-Pacific is anticipated to grow at the highest rate in the insulin syringes market during the forecast period, followed by LAMEA

Region wise, North America acquired a major share of insulin syringes market in 2020 owing, high prevalence of diabetes, increase in healthcare expenditures and presence of key players of insulin syringe manufacturers. However, Asia-Pacific is expected to grow at the highest rate during the forecast period, owing to rise in diabetes prevalence in Asia- Pacific (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, &, continued expansion of advanced medical facilities in emerging countries (such as China & India) are the key factors anticipating the growth of market.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.